These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14870958)

  • 1. Discontinuation symptoms associated with nefazodone.
    Tamam L; Ozpoyraz N
    J Psychopharmacol; 2003 Dec; 17(4):447-50. PubMed ID: 14870958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation symptoms with nefazodone.
    Rajagopalan M; Little J
    Aust N Z J Psychiatry; 1999 Aug; 33(4):594-7. PubMed ID: 10483857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment.
    Mischoulon D; Opitz G; Kelly K; Fava M; Rosenbaum JF
    Depress Anxiety; 2004; 19(1):43-50. PubMed ID: 14978785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.
    Dallal A; Chouinard G
    J Clin Psychopharmacol; 1998 Aug; 18(4):343-4. PubMed ID: 9690703
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic dose range of nefazodone in the treatment of major depression.
    Robinson DS; Marcus RN; Archibald DG; Hardy SA
    J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefazodone: a novel antidepressant.
    Goldberg RJ
    Psychiatr Serv; 1995 Nov; 46(11):1113-4. PubMed ID: 8564497
    [No Abstract]   [Full Text] [Related]  

  • 7. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure.
    Lespérance F; Frasure-Smith N; Laliberté MA; White M; Lafontaine S; Calderone A; Talajic M; Rouleau JL
    Can J Psychiatry; 2003 Nov; 48(10):695-701. PubMed ID: 14674053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetically induced benzodiazepine withdrawal.
    Ninan PT
    Psychopharmacol Bull; 2001; 35(4):94-100. PubMed ID: 12397859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
    Castañeda R; Levy R; Westreich LM; Sussman N
    J Clin Psychiatry; 1996 Oct; 57(10):485-6. PubMed ID: 8909335
    [No Abstract]   [Full Text] [Related]  

  • 10. Nefazodone overdose.
    Gaffney PN; Schuckman HA; Beeson MS
    Ann Pharmacother; 1998 Nov; 32(11):1249-50. PubMed ID: 9825097
    [No Abstract]   [Full Text] [Related]  

  • 11. Nefazodone-associated subjective complaints of burning sensations.
    Lerner V; Matar MA; Polyakova I
    J Clin Psychiatry; 2000 Mar; 61(3):216-7. PubMed ID: 10817110
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuation symptoms in depression and anxiety disorders.
    Baldwin DS; Montgomery SA; Nil R; Lader M
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):73-84. PubMed ID: 16359583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nefazodone withdrawal symptoms.
    Benazzi F
    Can J Psychiatry; 1998 Mar; 43(2):194-5. PubMed ID: 9533975
    [No Abstract]   [Full Text] [Related]  

  • 15. Probable nefazodone-induced mania in a patient with unreported bipolar disorder.
    Zaphiris HA; Blaisdell GD; Jermain DM
    Ann Clin Psychiatry; 1996 Dec; 8(4):207-10. PubMed ID: 8986316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nefazodone for PTSD.
    Domon SE; Andersen MS
    J Am Acad Child Adolesc Psychiatry; 2000 Aug; 39(8):942-3. PubMed ID: 10939221
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of open-label nefazodone treatment in patients with panic disorder.
    Papp LA; Coplan JD; Martinez JM; de Jesus M; Gorman JM
    J Clin Psychopharmacol; 2000 Oct; 20(5):544-6. PubMed ID: 11001239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
    Hertzberg MA; Feldman ME; Beckham JC; Moore SD; Davidson JR
    Ann Clin Psychiatry; 2002 Dec; 14(4):215-21. PubMed ID: 12630657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration.
    Khouzam HR
    J Psychosoc Nurs Ment Health Serv; 2000 Aug; 38(8):20-5. PubMed ID: 10959472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nefazodone: single versus twice daily dose.
    Voris JC; Shaurette GN; Sebastian PS; Will-Wallace LA
    Pharmacotherapy; 1998; 18(2):379-80. PubMed ID: 9545158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.